))
Test Innovations in Personalized Medicine: Overcoming Challenges and Embracing Change
Manage episode 377513947 series 3396813
コンテンツは Perry Dimas によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Perry Dimas またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Using genomics or other biomarkers to improve health care is the essence of Personalized Medicine according to today’s guest, Dr. Bruce Quinn. Moving forward with novel diagnostic testing could prove challenging for a variety of reasons, one of them being a disruption to the overall healthcare industry. If one test could replace multiple, costly tests, then the ROI for certain payors goes down.
Join us as we also discuss:
- The other challenges facing new tests
- Where test identifiers are heading
- The indirect interest of insurance sales
Dr. Quinn is the Principal at Bruce Quinn Associates LLC and is an expert in Medicare policy for innovative technology. His initial career was as a full-time medical school faculty member. Armed with an MBA in 2001, he shifted to a career in strategy consulting. He served as a regional Medicare Part B medical director 2004-2008. He has worked for a global consulting firm, Accenture, as well as for two DC-based health policy firms.
Since 2016, he has been an independent consulting primarily focused on genomics and digital technologies. His services include product planning and reimbursement pathways for innovators, as well as due diligence investigations for investors. His website on health policy and new technology, “Discoveries in Health Policy,” has had over a million views, holds 2000 articles, and has hundreds of subscribers from industry, academia, and government. Dr. Quinn is based in Los Angeles.
—----
Stay connected with our host, Perry Dimas, here on LinkedIn!
23 つのエピソード
シェア
